EBR Systems, Inc. (EBRCZ)
| Market Cap | 78.83M -76.5% |
| Revenue (ttm) | 6.45M +3,691.8% |
| Net Income | -60.76M |
| EPS | -0.13 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,000 |
| Open | 0.0828 |
| Previous Close | 0.0828 |
| Day's Range | 0.0828 - 0.0828 |
| 52-Week Range | 0.0827 - 1.5000 |
| Beta | 0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Feb 25, 2027 |
About EBR Systems
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization therapy (SOLVE-CRT), an investigational device exemption. The company was incorporated in 2003 and is headquartered in Sunnyvale, California. [Read more]
Financial Performance
Financial StatementsNews
EBR Systems Earnings Call Transcript: Q3 2026
Q3 WiSE procedures were 40, below expectations, as commercial strategy pivots from broad site launches to deeper support in existing accounts. Training, facility activation, FDA/CMS decisions and reimbursement remain key growth catalysts and execution dependencies.
EBR Systems Earnings release: Q3 2026
EBR Systems released its Q3 2026 earnings on October 13, 2026, summarizing the period's financial results.
EBR Systems Transcript: EGM 2026
The meeting addressed two key proposals for the ratification and approval of CDI issuances at AUD 0.38 per CDI, both of which were supported by the board. Voting was conducted by poll, with results to be released to the ASX and posted on the company’s website.
EBR Systems Earnings Call Transcript: Q2 2026
Q2 saw continued commercial growth, with expanded hospital contracts, physician training, and a major capital raise to support U.S. scale-up. A recent patient fatality was addressed as a known risk, with no impact on business fundamentals or rollout pace.
EBR Systems Earnings release: Q2 2026
EBR Systems released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
EBR Systems Slides: Q2 2026
EBR Systems has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
EBR Systems Slides: Investor presentation
EBR Systems has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
EBR Systems Earnings Call Transcript: Q1 2026
Q1 revenue surged to $2.4 million from zero year-over-year, driven by strong physician engagement and expanding hospital adoption. Investments in sales and manufacturing are fueling growth, with a new facility and major hospital contracts supporting long-term scale.
EBR Systems Earnings release: Q1 2026
EBR Systems released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
EBR Systems Transcript: AGM 2026
The meeting highlighted a transformative year with FDA approval, reimbursement wins, and commercial rollout of the WiSE System. All board and compensation proposals were put to vote, financials were reviewed, and governance standards upheld. Voting results will be published.
EBR Systems Slides: FY 2026
EBR Systems has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 28, 2026.
EBR Systems Earnings Call Transcript: Q4 2025
FDA approval and commercial rollout of leadless left ventricular pacing drove strong Q4 growth, with revenue over $900,000 and patient volume doubling sequentially. High physician engagement, robust reimbursement, and no direct competitors support continued expansion, while a new manufacturing facility and vertical integration are underway.
EBR Systems Annual report: Q4 2025
EBR Systems has published its Q4 2025 annual report on March 19, 2026.
EBR Systems Earnings release: Q4 2025
EBR Systems released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
EBR Systems Transcript: EGM 2026
Two key proposals were presented: a reverse stock split at a flexible ratio and ratification of securities issued in May 2025. Voting was conducted by poll, with results to be published on the ASX and company website.
EBR Systems Slides: Investor presentation
EBR Systems has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
EBR Systems Transcript: EGM 2026
The meeting focused on a proposal to consolidate common shares, freeing up authorized shares for future financing and strategic flexibility. Shareholders were assured that CDI holdings and value would not be affected, and no immediate plans for capital raising or U.S. listing were disclosed.
EBR Systems Slides: FY 2026
EBR Systems has posted slides in relation to its FY 2026 quarterly earnings report, which was published on January 20, 2026.
EBR Systems Transcript: 44th Annual J.P. Morgan Healthcare Conference
A unique leadless pacemaker for left ventricular pacing has launched with FDA approval and strong reimbursement, targeting a $5.8B U.S. market. Early adoption is on track, with modular compatibility enabling new therapies and a disciplined commercial rollout supporting growth.
EBR Systems Earnings release: Q3 2025
EBR Systems released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.